Breast cancer (BC) is the most frequent cancer diagnosed in women worldwide. This
heterogeneous disease can be classified into four molecular subtypes (luminal A, luminal B …

Triple-negative breast cancer (TNBC) remains the most challenging breast cancer subtype
to treat. To date, therapies directed to specific molecular targets have rarely achieved …

Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly developing a
strong evidence base for use in patients with cancer. The European Society for Medical …

Triple-negative breast cancer (TNBC) is not a unique disease, encompassing multiple
entities with marked histopathological, transcriptomic and genomic heterogeneity. Despite …

Decades of research in molecular oncology have brought about promising new therapies
which are designed to target specific molecules which promote tumor growth and survival …

The advent of HER2-directed therapies has significantly improved the outlook for patients
with HER2-positive early stage breast cancer. However, a significant proportion of these …

The epidermal growth factor receptor (EGFR) is a cell-surface receptor belonging to ErbB
family of tyrosine kinase and it plays a vital role in the regulation of cell proliferation, survival …

Microtubules play a crucial role in multiple cellular functions including mitosis, cell signaling,
and organelle trafficking, which makes the microtubule an important target for cancer …

Purpose Preclinical studies in ErbB2-positive cell lines demonstrated a synergistic
interaction between lapatinib and trastuzumab, suggesting that dual blockade is more …

Purpose Cross-talk between human epidermal growth factor receptors and hormone
receptor pathways may cause endocrine resistance in breast cancer. This trial evaluated the …